Panic Disorder

• Amygdala hyperresponsivity and fear circuit dysfunction: The amygdala, central to threat detection and fear conditioning, demonstrates heightened activation and connectivity with the insula and anterior cingulate cortex in panic disorder. This neural circuitry becomes sensitized such that interoceptive cues (internal bodily sensations) are misinterpreted as dangerous threats, triggering a cascade of autonomic activation. The ventromedial prefrontal cortex, which normally exerts top-down inhibition of amygdala reactivity, shows reduced activation and connectivity, resulting in impaired fear extinction and emotional regulation. This creates a self-perpetuating cycle where fear of panic begets panic attacks.

• Dysregulation of GABAergic neurotransmission: Gamma-aminobutyric acid (GABA) is the primary inhibitory neurotransmitter in the central nervous system. Patients with panic disorder demonstrate reduced GABAergic transmission, particularly at GABA-A receptors in the amygdala, anterior cingulate cortex, and insula. This reduced inhibitory tone fails to dampen excitatory drive, allowing threat signals to propagate unchecked. The reduced benzodiazepine receptor binding observed on neuroimaging likely reflects compensatory downregulation secondary to chronically elevated anxiety. Genetic polymorphisms affecting GABA receptor subunit composition (particularly the alpha-2 subunit) confer vulnerability to panic disorder.

• Serotonergic system dysfunction and the locus coeruleus hypothesis: The dorsal raphe nucleus, the major source of central serotonin, projects widely to limbic and cortical structures involved in anxiety regulation. Panic disorder involves both hypofunction of serotonergic tone in some brain regions and dysregulation of serotonin receptor expression and sensitivity. Additionally, the locus coeruleus (LC), the brain's primary noradrenergic nucleus, demonstrates increased baseline activity and heightened reactivity to stressors in panic disorder. The LC innervates the amygdala, bed nucleus of the stria terminalis, and prefrontal cortex; excessive LC firing is thought to trigger the acute panic attack. Yohimbine (an alpha-2 antagonist that increases LC firing) reliably provokes panic in susceptible individuals, demonstrating the causal role of this system.

• Interoceptive conditioning and the false suffocation alarm hypothesis: Patients with panic disorder demonstrate heightened interoceptive awareness—an abnormally sensitive perception of internal bodily sensations. Through classical conditioning, initially neutral interoceptive cues (mild tachycardia, slight dyspnea, dizziness) become associated with danger, triggering conditioned fear responses. Papp's false suffocation alarm theory proposes that panic attacks represent a misfire of the brain's respiratory control system, where the involuntary suffocation alarm is activated despite adequate oxygenation. This explains why dyspnea and CO2 hypersensitivity are so prominent in panic attacks; patients truly perceive a threat to their survival. This mechanism is supported by observation that CO2 inhalation and voluntary hyperventilation reliably provoke panic in susceptible individuals.

• Abnormal CO2 and acid-base chemoreception: The brainstem chemoreceptors that monitor CO2 and pH are hypersensitive in panic disorder. Additionally, there is altered perception and interpretation of CO2 levels; patients catastrophically misinterpret minor increases in CO2 (from hyperventilation or physical exertion) as indicating dangerously elevated levels. This creates a vicious cycle: anxiety → hyperventilation → respiratory alkalosis → dizziness and paresthesias → catastrophic misinterpretation → increased anxiety.

• Genetic predisposition and environmental interaction: Twin studies indicate heritability of approximately 30-40% for panic disorder. Candidate genes affecting serotonin transporters (5-HTT), brain-derived neurotrophic factor (BDNF), and genes regulating amino acid neurotransmission have been implicated. However, genetic vulnerability only manifests in the context of environmental stressors—adverse childhood experiences, trauma, chronic stress, and major life transitions are significant environmental triggers. This reflects a classic diathesis-stress model where biological predisposition is necessary but insufficient without environmental precipitation.

• Primary (idiopathic) panic disorder: The majority of cases arise without identifiable organic precipitant, representing the core expression of the neurobiological vulnerabilities described above. Onset is typically spontaneous, though retrospective evaluation often identifies a period of heightened stress preceding the first panic attack. The absence of identifiable medical cause distinguishes this from secondary panic attacks.

• Genetic predisposition and family history: First-degree relatives of patients with panic disorder have a 5-8 fold increased risk of developing the condition, and concordance in monozygotic twins exceeds 30%. Multiple candidate genes have been identified through genome-wide association studies, affecting serotonergic, GABAergic, and glutamatergic neurotransmission. No single genetic variant confers substantial risk; rather, multiple variants of small effect combine to create vulnerability.

• Psychological and environmental stressors: Significant life stressors (loss, separation, major illness), chronic stress, occupational strain, and major life transitions frequently precede panic onset. Childhood adversity, including physical or sexual abuse, parental loss, and parental anxiety disorders, substantially increases risk. The quality of early attachment relationships and parenting style (particularly overprotective or unpredictable parenting) influences risk. These environmental factors likely act through epigenetic mechanisms, altering gene expression patterns in stress-response systems without changing the DNA sequence itself.

• Substance use and withdrawal: Chronic stimulant use (cocaine, amphetamines, excessive caffeine) can precipitate or exacerbate panic attacks through enhanced noradrenergic tone. Alcohol dependence frequently co-occurs, and alcohol withdrawal specifically can trigger severe panic attacks through disinhibition of brain circuits normally suppressed by GABAergic effects. Cannabis use, particularly in high-THC strains, reliably provokes panic attacks in susceptible individuals.

• Medical conditions producing panic-like symptoms (secondary panic): Hyperthyroidism, pheochromocytoma, hypoglycemia, cardiac arrhythmias, and pulmonary embolism must be excluded. Hyperparathyroidism, seizure disorders (particularly temporal lobe epilepsy), and vestibular dysfunction can produce panic-like episodes. Importantly, panic attacks can occur as a feature of these medical conditions, but the diagnosis of panic disorder requires the typical panic attack syndrome in the absence of an identified medical cause. The timeline and context help distinguish primary panic disorder from medical mimics.

• Medication-induced panic: SSRIs paradoxically can increase anxiety and panic early in treatment; stimulating medications (methylphenidate, decongestants containing pseudoephedrine), corticosteroids, and some anesthetics can trigger panic. Discontinuation of sedating medications or benzodiazepines can precipitate breakthrough panic as rebound anxiety emerges.

• Personality factors and psychological traits: High neuroticism (emotional reactivity and negative affectivity), perfectionism, and anxious attachment styles increase vulnerability. Individuals with heightened harm avoidance and interoceptive sensitivity are at greater risk. Some evidence suggests panic-prone individuals may have constitutionally elevated baseline physiological arousal.

• Cardiovascular symptoms: Palpitations, chest pain or pressure, and sensation of impending cardiac collapse are nearly universal. Patients report tachycardia (often 100-150+ bpm) with irregular or forceful beats. Chest discomfort is frequently described as crushing, squeezing, or sharp, closely mimicking acute coronary syndrome. Blood pressure elevations (systolic 130-160 mmHg) reflect sympathetic activation. These symptoms arise from catecholamine surge causing direct myocardial effects and increased contractility; the fear intensifies focus on these sensations, creating a vicious cycle.

• Respiratory symptoms: Dyspnea (sensation of breathlessness), hyperventilation, throat tightness, and sensation of choking or smothering occur in >90% of attacks. These reflect both actual hyperventilation and anxiety-driven catastrophic misinterpretation of normal respiratory sensations. Hyperventilation produces respiratory alkalosis, leading to decreased ionized calcium and increased neuromuscular irritability, manifesting as paresthesias (see below). The sensation of suffocation is deeply frightening, activating primitive survival circuits.

• Neurological and vestibular symptoms: Dizziness, lightheadedness, vertigo, and unsteadiness are common. These result from hyperventilation-induced hypocapnia, decreased cerebral blood flow, and anxiety-driven somatosensory amplification. Paresthesias (tingling in hands, feet, lips, and face) reflect the mild hypocalcemia and respiratory alkalosis from hyperventilation. Depersonalization (feeling detached from one's body) and derealization (feeling the environment is unreal or dreamlike) represent dissociative responses to overwhelming anxiety; these are particularly distressing as they convince patients something is catastrophically wrong with their mind.

• Gastrointestinal symptoms: Nausea, abdominal cramping, diarrhea, and sensation of choking reflect sympathetic activation of GI smooth muscle and increased acid secretion. These sensations often occur in the prodrome or aftermath of panic rather than the acute attack itself.

• Autonomic symptoms: Diaphoresis (profuse sweating), chills, hot flashes, and piloerection reflect catecholamine-driven thermoregulatory dysregulation. Tremor, particularly fine tremor of the hands, is evident.

• Cognitive symptoms: The patient experiences intense fear of dying, fear of losing control or "going crazy," and catastrophic misinterpretation of bodily sensations. There is typically a sense of unreality. Thought content focuses on imminent doom, and concentration is impossible. Cognitive distortions (overestimation of threat, underestimation of coping ability) amplify anxiety.

Important clinical variants

• Nocturnal panic attacks occur during sleep, awakening the patient from NREM sleep with full panic symptomatology. The absence of a clear trigger (the person is asleep) particularly frightens patients and is harder to treat with cognitive techniques.
• Limited-symptom panic attacks have fewer than four panic symptoms but otherwise resemble full panic attacks. They predict progression to full panic disorder.
• Panic with prominent dissociation features severe depersonalization/derealization, which can be particularly distressing and is sometimes harder to treat with standard approaches.

DSM-5-TR diagnostic criteria for Panic Disorder

• Recurrent unexpected panic attacks (at least two unprovoked attacks)
• At least one attack followed by ≥1 month of persistent worry about future attacks, their consequences, or significant behavioral change related to attacks
• The panic attacks are not attributable to the direct physiological effects of a medical condition or substance
• The disturbance is not better explained by another mental disorder (e.g., agoraphobia, PTSD, social anxiety disorder)

Diagnostic approach

• Detailed history: Onset and trajectory of panic attacks (sudden vs. gradual); triggers (are attacks truly unexpected, or do identifiable triggers exist?); content of catastrophic thoughts; intoxicant use; prior medical evaluation; family history of anxiety/depression; past trauma.
• Screening for agoraphobia: Clarify avoidance patterns and situations feared. Agoraphobia can occur with or without panic disorder but has prognostic significance.
• Assessment of functional impairment: Quantify impact on work, relationships, and quality of life. Use validated instruments such as the Panic Disorder Severity Scale (PDSS) (0-28 scale; scores >9 suggest moderate-to-severe disorder) or the GAD-7 (Generalized Anxiety Disorder 7-item scale; though designed for generalized anxiety, it captures overall anxiety severity). The Agoraphobic Cognitions Questionnaire (ACQ) and Body Sensations Questionnaire (BSQ) assess catastrophic thoughts and interoceptive fear, respectively.

Medical workup to exclude secondary causes

• Thyroid function tests (TSH, free T4): Hyperthyroidism can produce panic-like symptoms with tachycardia, tremor, anxiety, and heat intolerance. TSH elevation or low-normal TSH with elevated free T4 suggests hyperthyroidism.
• Complete blood count and metabolic panel: Hypoglycemia (fasting glucose <70 mg/dL), hypercalcemia (calcium >10.5 mg/dL, as in hyperparathyroidism), and hypomagnesemia can precipitate panic-like episodes.
• 12-lead electrocardiogram: Rule out primary cardiac arrhythmias (especially sinus tachycardia, atrial fibrillation, long QT syndrome) that can produce palpitations and chest discomfort. Baseline ECG before SSRI initiation is prudent, particularly for QT-prolonging agents in susceptible patients.
• Cardiac evaluation: If chest pain is prominent or cardiac risk factors present, troponin and echocardiography may be warranted to exclude acute coronary syndrome or structural disease. However, in young, low-risk individuals with classic panic presentations, extensive cardiac workup is often unnecessary and can reinforce health anxiety.
• Toxicology screen: Screen for stimulant use (cocaine, amphetamines) and assess caffeine intake.
• Holter monitor or event recorder: If palpitations are prominent and intermittent, ambulatory cardiac monitoring can exclude arrhythmia as the primary etiology.

• Generalized Anxiety Disorder (GAD): Characterized by chronic, pervasive worry without discrete panic attacks. Anxiety in GAD is more diffuse and sustained; in panic disorder, anxiety is episodic and concentrated around panic attacks.
• Agoraphobia without panic disorder: Anxiety and avoidance of situations without a history of panic attacks (rare but occurs, often triggered by other feared outcomes like panic attack itself or other medical catastrophes).
• Social Anxiety Disorder: Anxiety is specifically triggered by social situations and public scrutiny; panic attacks occur only in feared social contexts.
• Specific Phobia: Fear and avoidance are triggered by a specific object or situation; anxiety is proportionate to objective threat.
• PTSD: Panic-like symptoms are contextualized within history of trauma and triggered by trauma reminders; re-experiencing, hypervigilance, and avoidance of trauma-related cues are present.
• **Medical conditions

Acute attack (in the ED or office)

• Reassurance and containment first: once ACS, PE, arrhythmia, hypoglycemia and thyrotoxicosis have been excluded, the attack is self-limited and terminates within minutes. Calm coaching of slow breathing addresses the hyperventilation–hypocapnia–paresthesia cycle. Routine benzodiazepine administration for every ED panic attack is not required and reinforces illness behavior.
• Short-acting benzodiazepine (e.g., lorazepam): reserve for severe, unremitting distress. Enhances GABA-A chloride conductance, restoring the inhibitory tone that is deficient in panic circuitry.

• SSRIs (representative: sertraline; paroxetine and fluoxetine also carry FDA approval for panic disorder): downregulate limbic serotonergic hyperreactivity over weeks. Start low and go slow — panic patients are exquisitely prone to early activation/jitteriness because they catastrophically misinterpret the initial noradrenergic-serotonergic surge. Full response takes 4–6 weeks; continue at least a year after remission before taper.
• SNRI (venlafaxine extended-release, FDA-approved for panic disorder) is an equivalent first-line alternative.
• CBT with interoceptive exposure: deliberately provoking feared sensations (hyperventilation, spinning, straw breathing) extinguishes conditioned fear of bodily cues; adds durable benefit that outlasts drug discontinuation.

Escalation and second line

• Benzodiazepine bridge (clonazepam, alprazolam): rapid relief while the SSRI takes effect, then taper. Not preferred monotherapy given tolerance, dependence, and interference with exposure-based learning.
• TCAs (imipramine, clomipramine) and MAOIs (phenelzine) are effective but relegated to refractory cases by anticholinergic, orthostatic, cardiac-conduction, and dietary-tyramine risks.

No surgical or procedural therapy exists.

Avoid

• Buspirone and beta blockers: ineffective for panic disorder itself.
• Benzodiazepines with opioids (FDA boxed warning: respiratory depression), in active alcohol/sedative use disorder, and in older adults (AGS Beers criteria).
• MAOI plus SSRI — serotonin syndrome; observe washout.
• In pregnancy, ACOG advises individualized risk–benefit discussion; paroxetine is generally avoided when an alternative is suitable.

Complications of the disorder

• Agoraphobia and progressive functional disability: avoidance is negatively reinforced by immediate anxiety relief, so the feared-situation list expands. Signaled by a patient who has stopped driving, working, or leaving home alone.
• Comorbid major depressive disorder with suicidality: shared serotonergic and HPA-axis dysregulation plus chronic demoralization. Panic disorder with comorbid depression carries increased suicide-attempt risk — screen for suicidal ideation at every visit; active ideation with plan is a psychiatric emergency.
• Alcohol and sedative use disorder: self-medication exploits GABA-A potentiation; withdrawal then provokes rebound panic, and alcohol withdrawal seizures/delirium tremens are emergencies.
• Iatrogenic harm from repeated workups: recurrent ED visits generate cumulative radiation, contrast nephropathy, and occasionally unnecessary angiography; paradoxically each negative test reinforces health anxiety.
• Missed organic disease: anchoring on "it's just panic" can conceal pulmonary embolism, ACS, arrhythmia, or pheochromocytoma — an emergency when dismissed. Suspect it with new onset after mid-life, syncope, hypoxemia, or objective ECG/troponin abnormality.

Complications of treatment

• SSRI/SNRI early activation: transient jitteriness and worsened panic in the first days from acute serotonergic stimulation; the classic reason a patient stops the drug and declares it "made me worse." Prevented by low starting dose.
• Serotonin syndrome: clonus, hyperreflexia, hyperthermia, agitation after adding a second serotonergic agent (triptan, linezolid, MAOI) — medical emergency.
• SIADH/hyponatremia, especially in older adults on SSRIs; presents as confusion, lethargy, or seizure.
• QT prolongation: dose-dependent with citalopram; FDA labeling caps the daily dose, with a lower ceiling in patients over 60 or with hepatic impairment.
• Antidepressant discontinuation syndrome: flu-like symptoms, dizziness, "brain zaps" — most notorious with paroxetine and venlafaxine (short half-lives).
• Benzodiazepine tolerance, dependence, falls, and cognitive impairment; abrupt cessation can cause withdrawal seizures — an emergency. Sexual dysfunction and weight change drive nonadherence with SSRIs.

• Peak within minutes is the defining tempo: a stem describing terror that crescendos in about 10 minutes and resolves in under half an hour, with a completely normal exam afterward, is panic — not ACS, not PE.
• Best next step in a young, low-risk patient with a classic attack: reassurance plus ECG and TSH, then start an SSRI and refer for CBT. Repeat cardiac catheterization or serial stress testing is the wrong answer and feeds health anxiety.
• SSRI + CBT is the answer, benzodiazepine is the distractor: per the APA panic disorder guideline, an SSRI (sertraline) or SNRI (venlafaxine ER) with CBT is first line; benzodiazepines are a short bridge only. Start low and go slow — early activation is the classic reason for perceived treatment failure.
• Buspirone and beta blockers do not treat panic disorder. Buspirone belongs to GAD; propranolol belongs to performance-type social anxiety.
• Hyperventilation buzzwords: perioral and acral paresthesias with carpopedal spasm reflect respiratory alkalosis lowering ionized calcium — the finding that tells you the symptoms are hyperventilation-driven, not hypocalcemic disease.
• Provocation testing is the classic association: sodium lactate infusion, CO2 inhalation, and yohimbine reproducibly trigger attacks in panic patients — the exam's link to the false suffocation alarm and locus coeruleus hypotheses.
• The one comorbidity examiners test: major depression with suicidal ideation. Always screen; panic with agoraphobia predicts the worst functional outcome.
• Age of onset is the medical-mimic trigger: first-ever "panic" after roughly mid-life, or attacks with sustained hypertension, headache, and diaphoresis, should push you toward pheochromocytoma; with weight loss, tremor, and heat intolerance, toward hyperthyroidism.
• Common trap: DSM-5-TR requires ≥1 month of anticipatory worry or behavioral change after an attack — isolated panic attacks in another disorder (PTSD, specific phobia) are coded as a specifier, not panic disorder.